Treatment of blastomycosis with higher doses of fluconazole

被引:54
作者
Pappas, PG
Bradsher, RW
Kauffman, CA
Cloud, GA
Thomas, CJ
Campbell, GD
Chapman, SW
Newman, C
Dismukes, WE
机构
[1] UNIV ALABAMA, DIV INFECT DIS, BIRMINGHAM, AL 35294 USA
[2] UNIV ALABAMA, MYCOSES STUDY GRP CENT UNIT, BIRMINGHAM, AL 35294 USA
[3] UNIV ALABAMA, CTR COMPREHENS CANC, BIOSTAT UNIT, BIRMINGHAM, AL 35294 USA
[4] UNIV ARKANSAS MED SCI, DIV INFECT DIS, LITTLE ROCK, AR 72205 USA
[5] ANN ARBOR VET AFFAIRS MED CTR, ANN ARBOR, MI USA
[6] UNIV MICHIGAN, SCH MED, ANN ARBOR, MI USA
[7] LOUISIANA STATE UNIV, MED CTR, SHREVEPORT, LA USA
[8] UNIV MISSISSIPPI, MED CTR, JACKSON, MS 39216 USA
[9] MED COLL GEORGIA, AUGUSTA, GA 30912 USA
关键词
D O I
10.1086/514539
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Recent clinical data suggest that fluconazole at daily doses of 200 to 400 mg for at least 6 months is moderately effective therapy for non-life-threatening blastomycosis. To examine the usefulness of higher doses of fluconazole therapy for this disorder, we conducted a multicenter, randomized, open-label study to determine the efficacy and safety of two different daily doses of fluconazole (400 and 800 mg) in the treatment of non-life-threatening blastomycosis, Of 39 patients evaluable for efficacy analysis, 34 (87%) were successfully treated, including 89% and 85% of patients who received 400 and 800 mg, respectively, Five (83%) of six patients for whom prior antifungal therapy had failed were successfully treated, The mean duration of therapy was 8.9 months for successfully treated patients. Nineteen patients (48%) reported adverse events, although most were minor, We conclude that fluconazole at daily doses of 400 to 800 mg for at least 6 months is effective therapy for non-life-threatening blastomycosis.
引用
收藏
页码:200 / 205
页数:6
相关论文
共 20 条
[1]   KETOCONAZOLE THERAPY FOR ENDEMIC BLASTOMYCOSIS [J].
BRADSHER, RW ;
RICE, DC ;
ABERNATHY, RS .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (06) :872-879
[2]  
BUSEY JF, 1972, AM REV RESPIR DIS, V105, P812
[4]   ITRACONAZOLE THERAPY FOR BLASTOMYCOSIS AND HISTOPLASMOSIS [J].
DISMUKES, WE ;
BRADSHER, RW ;
CLOUD, GC ;
KAUFFMAN, CA ;
CHAPMAN, SW ;
GEORGE, RB ;
STEVENS, DA ;
GIRARD, WM ;
SAAG, MS ;
BOWLESPATTON, C .
AMERICAN JOURNAL OF MEDICINE, 1992, 93 (05) :489-497
[5]  
GALGIANI JN, 1990, REV INFECT DIS, V12, pS272
[6]  
GALLIS HA, 1990, REV INFECT DIS, V12, P308
[7]   FLUCONAZOLE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC POTENTIAL IN SUPERFICIAL AND SYSTEMIC MYCOSES [J].
GRANT, SM ;
CLISSOLD, SP .
DRUGS, 1990, 39 (06) :877-916
[8]   Role of azoles in antifungal therapy [J].
Kauffman, CA .
CLINICAL INFECTIOUS DISEASES, 1996, 22 :S148-S153
[9]   TREATMENT OF NORTH AMERICAN BLASTOMYCOSIS - 10 YEARS EXPERIENCE [J].
LOCKWOOD, WR ;
ALLISON, F ;
BATSON, BE ;
BUSEY, JF .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1969, 100 (03) :314-+
[10]   COMPARATIVE ACTIVITIES OF UK-49,858 AND AMPHOTERICIN-B AGAINST BLASTOMYCES-DERMATITIDIS INFECTIONS IN MICE [J].
LYMAN, CA ;
SUGAR, AM ;
DIAMOND, RD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 29 (01) :161-162